Merus’s Promising Oncology Advancements Justify Buy Rating Amidst Strong Clinical Results

William Blair analyst Matt Phipps has reiterated their bullish stance on MRUS stock, giving a Buy rating yesterday.

Matt Phipps has given his Buy rating due to a combination of factors that highlight Merus’s promising position in the oncology market. The recent data update from the American Society of Clinical Oncology (ASCO) annual meeting showcased impressive results for Merus’s petosemtamab in combination with Keytruda, particularly in treating first-line recurrent or metastatic head and neck squamous cell carcinoma. The updated dataset revealed a median progression-free survival of 9.0 months and a 12-month overall survival rate of 79%, indicating strong efficacy.
Additionally, the overall response rate was consistent with previous findings, and there was a notable improvement in the complete response rate, with more patients achieving complete remission. These results underscore petosemtamab’s potential as a leading treatment in its category. With the anticipation of top-line results from Phase III studies and the potential for significant market opportunities, Phipps sees considerable upside potential for Merus’s stock, justifying the Buy rating.

Phipps covers the Healthcare sector, focusing on stocks such as Incyte, Merus, and Bristol-Myers Squibb. According to TipRanks, Phipps has an average return of -10.5% and a 34.40% success rate on recommended stocks.

In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $110.00 price target.